P
Philip J. Rosenfeld
Researcher at University of Miami
Publications - 358
Citations - 32577
Philip J. Rosenfeld is an academic researcher from University of Miami. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 77, co-authored 325 publications receiving 28506 citations. Previous affiliations of Philip J. Rosenfeld include Massachusetts Eye and Ear Infirmary & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Swept-source optical coherence tomography angiography reveals choriocapillaris alterations in eyes with nascent geographic atrophy and drusen-associated geographic atrophy.
Eric M. Moult,Nadia K. Waheed,Eduardo A. Novais,Eduardo A. Novais,WooJhon Choi,ByungKun Lee,Stefan B Ploner,Stefan B Ploner,Emily Cole,Ricardo N. Louzada,Ricardo N. Louzada,Chen D. Lu,Philip J. Rosenfeld,Jay S. Duker,James G. Fujimoto +14 more
TL;DR: OCTA imaging of the CC revealed focal CC flow impairment associated with areas of nGA and DAGA, as well as diffuseCC flow impairment throughout the imaged field, which should prove useful for understanding the pathogenesis of n GA and D AGA.
Journal ArticleDOI
Swept-source OCT angiography of macular telangiectasia type 2.
Mariana R. Thorell,Qinqin Zhang,Yanping Huang,Lin An,Mary K Durbin,Michal Laron,Utkarsh Sharma,Paul F. Stetson,Giovanni Gregori,Ruikang K. Wang,Philip J. Rosenfeld +10 more
TL;DR: Evaluating the central macular microvascular network in patients with macular telangiectasia type 2 (MacTel2) using optical coherence tomography (OCT)-based microangiography (OMAG) provided detailed, depth- resolved information about the perifoveal macularmicrovasculature in MacTel2.
Journal ArticleDOI
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
TL;DR: There is now ample evidence that anti-VEGF therapies are viable treatment options for neovascular ocular disease, and large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.
Journal ArticleDOI
TOWARD QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY: Visualizing Blood Flow Speeds in Ocular Pathology Using Variable Interscan Time Analysis
Stefan B Ploner,Eric M. Moult,WooJhon Choi,Nadia K. Waheed,ByungKun Lee,Eduardo A. Novais,Emily Cole,Benjamin Potsaid,Lennart Husvogt,Julia Schottenhamml,Julia Schottenhamml,Andreas Maier,Philip J. Rosenfeld,Jay S. Duker,Joachim Hornegger,James G. Fujimoto +15 more
TL;DR: The method was found useful, in a small case series, for visualizing blood flow speeds in a variety of ocular diseases and serves as a step toward quantitative optical coherence tomography angiography.
Journal ArticleDOI
Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
Nizar Saleh Abdelfattah,Hongyang Zhang,David S. Boyer,Philip J. Rosenfeld,William J. Feuer,Giovanni Gregori,Srinivas R. Sadda +6 more
TL;DR: Baseline drusen volume appears to be an important predictor for the development of late AMD within 2 years in eyes that have fellow eyes being actively treated for MNV, suggesting that OCT-derived drUSen volume measurements may be a useful biomarker to identify eyes at the highest risk for progression to late AMD.